Monopar Therapeutics Says Investigational Wilson Disease Treatment Shows Neurologic Improvement

MT Newswires Live

Sep 15, 2025

Monopar Therapeutics (MNPR) said Sunday its ALXN1840 investigational therapy for Wilson disease showed "statistically significant neurologic improvement from baseline" in an analysis of data from three clinical trials.

The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.

The analysis, which included safety data from a fourth clinical trial, showed the drug had a "favorable" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567192375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567192375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567192375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567192375","market":"sh","top_or_hot":-1,"title":"Monopar Therapeutics Says Investigational Wilson Disease Treatment Shows Neurologic Improvement","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> (MNPR) said Sunday its ALXN1840 investigational therapy for Wilson disease showed \"statistically significant neurologic improvement from baseline\" in an analysis of data from three clinical trials.</p><p>The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.</p><p>The analysis, which included safety data from a fourth clinical trial, showed the drug had a \"favorable\" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monopar Therapeutics Says Investigational Wilson Disease Treatment Shows Neurologic Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonopar Therapeutics Says Investigational Wilson Disease Treatment Shows Neurologic Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-15 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> (MNPR) said Sunday its ALXN1840 investigational therapy for Wilson disease showed \"statistically significant neurologic improvement from baseline\" in an analysis of data from three clinical trials.</p><p>The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.</p><p>The analysis, which included safety data from a fourth clinical trial, showed the drug had a \"favorable\" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567192375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567192375","pubTimestamp":1757922251,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Monopar Therapeutics  said Sunday its ALXN1840 investigational therapy for Wilson disease showed \"statistically significant neurologic improvement from baseline\" in an analysis of data from three clinical trials.The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.The analysis, which included safety data from a fourth clinical trial, showed the drug had a \"favorable\" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics","BK4139":"生物科技"},"translate_title":"Monopar Therapeutics表示威尔逊病研究治疗显示神经系统改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) said Sunday its ALXN1840 investigational therapy for Wilson disease showed \"statistically significant neurologic improvement from baseline\" in an analysis of data from three clinical trials.The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.The analysis, which included safety data from a fourth clinical trial, showed the drug had a \"favorable\" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}